

TRADEMARK ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

ETAS ID: TM569519

SUBMISSION TYPE:	RESUBMISSION		
NATURE OF CONVEYANCE:	ASSIGNMENT OF THE ENTIRE INTEREST AND THE GOODWILL		
RESUBMIT DOCUMENT ID:	900537568		
CONVEYING PARTY DATA			
Name	Formerly	Execution Date	Entity Type
ECR Pharmaceuticals Co., Inc.		12/03/2018	Corporation: DELAWARE
RECEIVING PARTY DATA			
Name:	Bausch Health Ireland Limited		
Street Address:	3013 Lake Drive		
Internal Address:	Citywest Business Campus		
City:	Dublin		
State/Country:	IRELAND		
Postal Code:	24		
Entity Type:	Company: IRELAND		
PROPERTY NUMBERS Total: 5			
Property Type	Number	Word Mark	
Registration Number:	3571599	BUPAP	
Registration Number:	2534771	DEXPAK	
Registration Number:	2551738	TAPERPAK	
Registration Number:	3261803	TUSSICAPS	
Serial Number:	77403543	LODRANE	
CORRESPONDENCE DATA			
Fax Number:	5853380015		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>			
Phone:	9497886000		
Email:	trademarks@bausch.com		
Correspondent Name:	Robert J. Gorman		
Address Line 1:	1400 N. Goodman Street		
Address Line 4:	Rochester, NEW YORK 14609		
ATTORNEY DOCKET NUMBER:	BIRL		
NAME OF SUBMITTER:	Matthew Marshall		
SIGNATURE:	/matthew marshall/		

DATE SIGNED:	03/30/2020
---------------------	------------

Total Attachments: 8

source=Corrected Assignment#page1.tif

source=Corrected Assignment#page2.tif

source=Corrected Assignment#page3.tif

source=Notice of Non-Recordation#page1.tif

source=Notice of Non-Recordation#page2.tif

source=Notice of Non-Recordation#page3.tif

source=Notice of Non-Recordation#page4.tif

source=Notice of Non-Recordation#page5.tif

INTELLECTUAL PROPERTY ASSIGNMENT

This Assignment Agreement, dated as of December 20th, 2018 (the "Agreement"), is made by and between ECR Pharmaceuticals Co., Inc. a Delaware corporation located at 400 Somerset Corporate Blvd. Bridgewater, NJ, 08807, USA ("Assignor") and Bausch Health Ireland Limited, a company established and existing under the laws of Ireland having its registered office at 3013 Lake Drive, Citywest Business Campus, Dublin 24, Ireland ("Assignee").

WHEREAS, the economic benefits and burdens of ownership with respect to the patent applications, granted patents and trademarks set forth on **Schedule A** (collectively, the "Assigned IP") were previously transferred by Assignor to Assignee on December 19th, 2014, and such rights are now owned solely by Assignee; and

WHEREAS, pursuant to this Agreement, Assignor desires to assign, convey and transfer, and Assignee desires to receive, all of Assignor's legal title to the Assigned IP.

NOW, THEREFORE, in consideration of the mutual promises set forth in this Agreement and for the other good and valuable consideration of one United States Dollar, the receipt of which is hereby acknowledged, the parties hereby agree as follows:

1. **Assignment of Assigned IP.** Assignor hereby assigns, conveys and transfers to Assignee, and Assignee hereby accepts, all of Assignor's right, title and interest in and to (i) the Assigned IP together with the goodwill of the business symbolized by the Assigned IP and (ii) all benefits, privileges, causes of action, common law rights, and remedies relating thereto throughout the world, including, without limitation, all of Assignor's rights to (a) apply for and maintain all registrations, renewals and/or extensions thereof, (b) bring actions and recover damages for past, present and future infringement or other violation thereof, and (c) grant licenses or other interests therein.

2. **Cooperation.** At Assignee's sole cost and expense, Assignor shall execute and deliver such other documents and take all other commercially reasonable actions which Assignee, its successors and/or assigns, may reasonably request to effect the terms of this Assignment, including its recordation in relevant state and national patent offices.

3. **Due Authorization.** Assignor hereby authorizes and requests the Commissioner of Patents of the United States and any other official of any applicable governmental authority to (a) record Assignee as assignee and owner of the entire right, title and interest in and to the Assigned IP and (b) issue any and all registrations from any and all applications for registration included in the Assigned IP to and in the name of Assignee.


4. **Successors and Assigns.** This Agreement and all of its provisions shall be binding upon and inure to the benefit of the parties hereto and their respective permitted successors and assigns.


5. **Governing Law; Jurisdiction.** This Agreement shall be governed in all respects by the laws of the State of New York, without giving effect to the principles of conflicts of law thereof.

6. **Counterparts.** This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but both of which together shall constitute one and the same instrument.

{signature page follows}

IN WITNESS WHEREOF, the parties have caused this instrument to be duly executed and delivered as of the date first written above.

ECR Pharmaceuticals Co., Inc.
By: 
Name: ROBERT A. GORMAN
Title: V.P. ASST. GENERAL COUNSEL

Bausch Health Ireland Limited,
By: 
Name: NICHOLAS V. KAVANAGH
Title: DIRECTOR

SCHEDULE A

ASSIGNED IP

TRADEMARKS

Mark Name	Country	Application Date	Application Number	Registration Date	Registration Number	Class Number
BUPAP	United States	2/22/2008	77403542	2/10/2009	3571599	5
DEXPAK (STYLIZED)	United States	2/18/2000	75923295	1/29/2002	2534771	5
LODRANE	United States	2/22/2008	77403543	2/10/2009	3571600	5
TAPERPAK	United States	2/29/2000	75931016	3/26/2002	2551738	5
TUSSICAPS	United States	7/8/2003	78271536	7/10/2007	3261803	5

PATENTS

Docket Number	Filing No	Country	Status	Application No.	Application Date	Publication Number	Patent Number
ECR-P05726		United States	GRANTED	10/570242	9/2/2004	2006-0286174-A1	7790201
ECR-P05726	C1	United States	GRANTED	12/850087	8/4/2010	2010-0316721-A1	8377480

INTELLECTUAL PROPERTY ASSIGNMENT

This Assignment Agreement, dated as of December ~~2014~~, 2018 (the "Agreement"), is made by and between ECR Pharmaceuticals Co., Inc. a Delaware corporation located at 400 Somerset Corporate Blvd. Bridgewater, NJ, 08807, USA ("Assignor") and Bausch Health Ireland Limited, a company established and existing under the laws of Ireland having its registered office at 3013 Lake Drive, Citywest Business Campus, Dublin 24, Ireland ("Assignee").

WHEREAS, the economic benefits and burdens of ownership with respect to the patent applications, granted patents and trademarks set forth on **Schedule A** (collectively, the "Assigned IP") were previously transferred by Assignor to Assignee on December 19th, 2014, and such rights are now owned solely by Assignee; and


WHEREAS, pursuant to this Agreement, Assignor desires to assign, convey and transfer, and Assignee desires to receive, all of Assignor's legal title to the Assigned IP;


NOW, THEREFORE, in consideration of the mutual promises set forth in this Agreement and for the other good and valuable consideration of one United States Dollar, the receipt of which is hereby acknowledged, the parties hereby agree as follows:

1. Assignment of Assigned IP. Assignor hereby assigns, conveys and transfers to Assignee, and Assignee hereby accepts, all of Assignor's right, title and interest in and to (i) the Assigned IP and (ii) all benefits, privileges, causes of action, common law rights, and remedies relating thereto throughout the world, including, without limitation, all of Assignor's rights to (a) apply for and maintain all registrations, renewals and/or extensions thereof, (b) bring actions and recover damages for past, present and future infringement or other violation thereof, and (c) grant licenses or other interests therein.
2. Cooperation. At Assignee's sole cost and expense, Assignor shall execute and deliver such other documents and take all other commercially reasonable actions which Assignee, its successors and/or assigns, may reasonably request to effect the terms of this Assignment, including its recordation in relevant state and national patent offices.
3. Due Authorization. Assignor hereby authorizes and requests the Commissioner of Patents of the United States and any other official of any applicable governmental authority to (a) record Assignee as assignee and owner of the entire right, title and interest in and to the Assigned IP and (b) issue any and all registrations from any and all applications for registration included in the Assigned IP to and in the name of Assignee.
4. Successors and Assigns. This Agreement and all of its provisions shall be binding upon and inure to the benefit of the parties hereto and their respective permitted successors and assigns.
5. Governing Law; Jurisdiction. This Agreement shall be governed in all respects by the laws of the State of New York, without giving effect to the principles of conflicts of law thereof.
6. Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but both of which together shall constitute one and the same instrument.

{signature page follows}

IN WITNESS WHEREOF, the parties have caused this instrument to be duly executed and delivered as of the date first written above.

ECR Pharmaceuticals Co., Inc.
By: 
Name: ROBERT A. GORMAN
Title: VP, ASST. GENERAL COUNSEL

Bausch Health Ireland Limited,
By: 
Name: NICHOLAS V. KAVANAGH
Title: DIRECTOR

SCHEDULE A

ASSIGNED IP

TRADEMARKS

Mark Name	Country	Application Date	Application Number	Registration Date	Registration Number	Class Number
BUPAP	United States	2/22/2008	77403542	2/10/2009	3571599	5
DEXPAK (STYLIZED)	United States	2/18/2000	75923295	1/29/2002	2534771	5
LODRANE	United States	2/22/2008	77403543	2/10/2009	3571600	5
TAPERPAK	United States	2/29/2000	75931016	3/26/2002	2551738	5
TUSSICAPS	United States	7/8/2003	78271536	7/10/2007	3261803	5

PATENTS

Docket Number	Filing No	Country	Status	Application No.	Application Date	Publication Number	Patent Number
ECR-P05726		United States	GRANTED	10/570242	9/2/2004	2006-0286174-A1	7790201
ECR-P05726	C1	United States	GRANTED	12/850087	8/4/2010	2010-0316721-A1	8377480

893476455v2